Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Racha Lydia Bouchouka has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phytochemical Analysis Using LC–MS/MS and Anticancer Activity of Asphodelus tenuifolius Roots: Cell Cycle Arrest, Apoptosis, and In Silico Insights

    by Racha Lydia Bouchouka, Farida Larit, Zahia Kabouche, Marlène Debiossat, Laurent Riou, Catherine Ghezzi, Francisco León, Ahmed Kabouche

    Asphodelus tenuifolius Cav. (Asphodelaceae) is traditionally used in North African ethnomedicine for inflammatory and oxidative stress‐related disorders. In this study, the hydroethanolic root extract was investigated by LC–HRMS/MS, leading to the identification of 58 metabolites, mainly flavonoids, anthraquinones, and cinnamic acid derivatives. Major constituents included luteolin, emodin, luteolin‐7‐ O ‐β‐D‐glucoside, subaphyllin ( N ‐ trans ‐feruloylputrescine), and N‐trans ‐feruloyltyramine. The extract showed moderate antiproliferative activity against MDA‐MB‐231 and PC‐3 cells, while flow cytometry revealed pronounced apoptosis induction (up to 85%) and significant G0/G1 cell‐cycle arrest. Molecular docking and target prediction suggested multitarget modulation of ERα, AR, AKT1, CDK2, and BCL‐2, particularly by aglycone metabolites. ADMET analysis indicated favorable drug‐likeness and safety profiles. These findings provide the first mechanistic evidence supporting the multitarget anticancer potential of A. tenuifolius roots and highlight their value as a source of bioactive anticancer scaffolds.

  • Open Access

    LC-HRMS/MS-Guided Profiling and Biological Evaluation of Stachys duriaei Extracts: Anticancer and Vasorelaxant Mechanisms via Apoptosis and Endothelium-Dependent Pathways

    by Racha Lydia Bouchouka, Zahia Kabouche, Marie Defondaumière, Marlène Debiossat, Catherine Ghezzi, Laurent Riou, Tarek H. Taha, Fehmi Boufahja, Hamdi Bendif, Stefania Garzoli

    Stachys duriaei (Lamiaceae) remains unexplored despite its pharmacological potential. In this study, for the first time, the antiproliferative, pro-apoptotic, cell cycle arrest, and vasorelaxant effects of the n-butanolic extract (BESD) and a VLC fraction (BF1SD) of Stachys duriaei were investigated. Antiproliferative activity was evaluated on PC3 and MDA-MB-231 cell lines via MTT assay (72 h). Apoptosis (Annexin V-FITC/PI) and cell cycle arrest (PI/RNase) were assessed by flow cytometry (24 h, 250–1000 µg/mL). Vasorelaxant effects were studied ex vivo on rat aortic rings. LC-HRMS/MS was used for phytochemical analysis. BESD showed higher antiproliferative activity (IC50: 196 ± 6 µg/mL for PC3, 182 ± 8 µg/mL for MDA-MB-231) than BF1SD (IC50: 281 ± 6 µg/mL and 273 ± 3 µg/mL, respectively). Apoptosis was dose-dependent, with BF1SD displaying a stronger effect at 1000 µg/mL (67.3 ± 0.5% vs. 49.9 ± 0.7% for BESD). BESD induced G2/M arrest, while BF1SD caused G0/G1 and G2/M arrest. Vasorelaxation was endothelium-dependent, likely mediated by NO. Identified compounds (hyperoside, luteolin-7-glucoside, and rutin) may contribute to these effects. BESD and BF1SD exhibit anticancer and vasorelaxant properties, indicating potential therapeutic use against cancer and cardiovascular diseases. Further studies are needed to isolate active compounds and confirm their effects in vivo.